title: [Secondary and tertiary prevention of allergic asthma in children].
abstract: Asthma is a disease of the lung epithelial barrier, most often associated with allergy in children. Asthma and allergy are two distinct diseases, but the phenotypic expression of asthma depends on atopic status. A better definition of phenotypes of asthma would result in better targeting of prevention and treatment modalities. Secondary prevention aims to prevent the onset of asthma and the acquisition of new sensitizations in sensitized children. Studies concerning allergen avoidance are insufficient to reach a definitive conclusion and antihistamines have not been shown to be effective. The results for specific immunotherapy suggest a benefit to prevent transition from allergic rhinitis to asthma and the onset of new sensitizations. Tertiary prevention aims to reduce symptoms in children with an existing allergic asthma diagnosis. The avoidance of known respiratory allergens will only be effective in combination with management of the whole environment. Specific immunotherapy has a real place, in combination with background therapy. It should be used according to guidelines in appropriately treated patients.
authors.affiliation: TSA 70034, Pôle Médicochirurgical de Pédiatrie, Hôpital des Enfants, 330 Avenue de Grande-Bretagne, 31059 Toulouse Cedex, France. rance.f@chu-toulouse.fr
authors.forename: F
authors.initials: F
authors.lastname: Rancé
authors.forename: A
authors.initials: A
authors.lastname: Deschildre
authors.forename: E
authors.initials: E
authors.lastname: Bidat
authors.forename: J
authors.initials: J
authors.lastname: Just
authors.forename: L
authors.initials: L
authors.lastname: Couderc
authors.forename: S
authors.initials: S
authors.lastname: Wanin
authors.forename: L
authors.initials: L
authors.lastname: Weiss
mesh_terms: D000293:Adolescent; D017668:Age of Onset; D000485:Allergens / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000209:etiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003888:Desensitization, Immunologic; D004781:Environmental Exposure; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000150:complications* / Q000517:prevention & control / Q000628:therapy; D008925:Mites; D010641:Phenotype; D012221:Rhinitis, Allergic, Perennial / Q000150:complications / Q000628:therapy; D012307:Risk Factors; D014777:Virus Diseases / Q000150:complications / Q000276:immunology
chemical_list: D000485:Allergens; D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents